PHARMACOGENETICS IN NEUROLOGICAL DISEASES

Abstract

Once a drug has access to the body of an organism, it plays a role in the determination of the specter of effect as well as in its intensity and duration. The extension with the drugs can be absorbed and carried to some target organ influences in its profile of strength and effect. The genetic variation can potentially affect the way an individual reply to the drug in some steps. The absorption of one drugs and its distribution to some organs are processed not only for the physicochemical properties of the drug, but also for endogenous molecules. Many of the susceptibility genes to the illnesses are also target of drugs and can simultaneously predispose the patients to the illness as well as the resistance to the treatment. The identification of new variants for illnesses predisposition can indicate new therapeutical targets and new pathways in the development of drugs and interventions. This systematic characterization of the nature and function of the genetic polymorphisms in enzymes and other advances in the pharmacogenetics has an extensive potential to improve the choice of the appropriate medicine and the correct dose for any patient in particular. In this article, we review the findings in pharmacogenetics of Epilepsy and Alzheimer’s disease.